26 Sep 2025 | 5 Mins Read
Sun Pharma, Cipla could get clobbered by Trump's US tariff
Flipitmoney
US President Donald Trump has imposed 100% tariffs on branded and patented drugs starting October 1, affecting 30-47% of Indian pharma companies' revenues linked to the US market. Shares of Sun Pharma, Cipla, and Dr. Reddy's fell up to 5% as a result. Dr. Reddy's is the most exposed with 47% of its revenue dependent on the US market, followed by Sun Pharma with 37%, and Cipla with 30%.